Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Giulia Viale"'
Autor:
Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Mariani, Daniela Aldrighetti, Giampaolo Bianchini, Luca Licata
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundNausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy of two antiemetic reg
Externí odkaz:
https://doaj.org/article/ca65e1973791437daeee94e6e27e63a0
Autor:
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we
Externí odkaz:
https://doaj.org/article/71af898d79424e0aa99424fea6092b45
Autor:
Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini, Matteo Maria Naldini, Carlo Bosi, Marta Piras, Matteo Dugo, Giampaolo Bianchini
Publikováno v:
Breast, Vol 69, Iss , Pp 330-341 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable respo
Externí odkaz:
https://doaj.org/article/8a3ed9d7d5134608972f9456bef24617
Autor:
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2355-2366 (2022)
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salv
Externí odkaz:
https://doaj.org/article/04d4128992ee4c3590607960b247f2b8
Autor:
Giulia Viale
Publikováno v:
Architectural Histories, Vol 10, Iss 1 (2022)
The Alps have often been considered a laboratory for architectural modernity. Buildings there were a litmus test to reveal the attitudes of 20th-century architects towards design. When Carlo Mollino designed a project for a Club Med hotel in Sestrier
Externí odkaz:
https://doaj.org/article/7a4b8d8336844963af0af038b7bbba17
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-9 (2019)
Abstract Background Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought bre
Externí odkaz:
https://doaj.org/article/844f5d0407b9497b8a9c19257991421f
Autor:
Stefania Morganti, Antonio Marra, Giulia Viale, Paola Zagami, Elham Sajjadi, Chiara Corti, Giuseppe Curigliano, Nicola Fusco, Carmen Criscitiello
Publikováno v:
Cancer Research. 82:P4-07
Background: In HER2-positive (HER2+) early breast cancer (eBC) treated with neoadjuvant therapy (NAT), HER2 loss on residual disease (RD) might be correlated with a dampen survival. Recent data from the KATHERINE trial showed a maintained benefit fro
Autor:
Richard D. Gelber, Erika Hitre, Andrea Gombos, Alan S. Coates, Alastair M. Thompson, Sole Investigators, Barbara Ruepp, J Chirgwin, Bettina Müller, Marie-Pascale Graas, Stefan Aebi, Subrina Farah, Joaquín Gavilá, Patrick Neven, K. Ribi, A Courtois, Christian Marth, E Abdi, Per Karlsson, Harold J. Burstein, Katsumasa Kuroi, Seamus O'Reilly, A. Goldhirsch, Thomas Ruhstaller, S. Loibl, Manuela Rabaglio, Marco Colleoni, G. Jerusalem, Giulia Viale, C Kamby, Sherene Loi, Edda Simoncini, Meredith M. Regan
Publikováno v:
Annals of Oncology. 32:1256-1266
BACKGROUND Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET). In anima
Autor:
Giulia Viale, Veronica Zuber, Patrizia Zucchinelli, Giovanna Petrella, Nadia Di Muzio, Luca Licata, Oreste Gentilini, Pietro Panizza, Maria Grazia Rodighiero, Daniela Aldrighetti, Lorenzo Sica, Rosa Di Micco, Giampaolo Bianchini, Alessia Rognone, Stefania Zambelli, M. Pasetti, Stefano Cascinu, Isabella Sassi
Publikováno v:
The Oncologist
Northern Italy has been one of the European regions reporting the highest number of COVID‐19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to t
Autor:
Umberto Malapelle, Marco Invernizzi, Nicola Fusco, Caterina Fumagalli, Elena Guerini-Rocco, Roberto Piciotti, Konstantinos Venetis, Elham Sajjadi, Giulia Viale, Carmen Criscitiello
Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are managed, including breast cancer. Unfortunately, only a relatively small number of breast cancer patients significantly respond to these treatments. To maximize the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfe1d81f8159afafe64fed549856425
http://hdl.handle.net/11588/881958
http://hdl.handle.net/11588/881958